As discussed above, vandetanib has additional activity versus EGFR and the adverse event profile of vandetanib in this and previous studies [17,36,37] is consistent with pharmacodynamic inhibition of both VEGFR (hypertension) and EGFR signaling (rash, diarrhea). This evidence concerns the gene KDR and Hypertension.